IMTX – Immatics N.V
Immatics N.V.IMTX
$4.14Name : Immatics N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $503,216,992.00
EPSttm : 0.15
Immatics N.V.
$4.14
4.28%$0.17Float Short %
7.73
Margin Of Safety %
Put/Call OI Ratio
0.46
EPS Next Q Diff
-0.88
EPS Last/This Y
-1.49
EPS This/Next Y
-0.2
Price
4.14
Target Price
16.86
Analyst Recom
1
Performance Q
-35.61
Relative Volume
0.45
Beta
0.92
Ticker: IMTX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-12 | IMTX | 4.57 | 0.61 | 3.38 | 8209 |
| 2025-03-13 | IMTX | 4.53 | 0.61 | 999.99 | 8196 |
| 2025-03-14 | IMTX | 4.55 | 0.61 | 999.99 | 8196 |
| 2025-03-17 | IMTX | 4.98 | 0.60 | 0.04 | 8144 |
| 2025-03-18 | IMTX | 5.11 | 0.57 | 0.00 | 8442 |
| 2025-03-19 | IMTX | 5.36 | 0.45 | 0.00 | 8985 |
| 2025-03-20 | IMTX | 5.29 | 0.46 | 0.37 | 8906 |
| 2025-03-21 | IMTX | 5.01 | 0.47 | 0.02 | 9041 |
| 2025-03-24 | IMTX | 5.01 | 0.49 | 14.00 | 8589 |
| 2025-03-25 | IMTX | 4.68 | 0.49 | 3.33 | 8588 |
| 2025-03-26 | IMTX | 4.53 | 0.49 | 2.86 | 8614 |
| 2025-03-27 | IMTX | 4.73 | 0.49 | 0.37 | 8638 |
| 2025-03-28 | IMTX | 4.63 | 0.49 | 0.00 | 8675 |
| 2025-03-31 | IMTX | 4.5 | 0.49 | 10.00 | 8677 |
| 2025-04-01 | IMTX | 3.99 | 0.49 | 0.00 | 8688 |
| 2025-04-02 | IMTX | 4.16 | 0.49 | 0.00 | 8688 |
| 2025-04-03 | IMTX | 3.83 | 0.49 | 0.10 | 8693 |
| 2025-04-04 | IMTX | 3.51 | 0.49 | 0.00 | 8712 |
| 2025-04-07 | IMTX | 3.7 | 0.49 | 0.08 | 8734 |
| 2025-04-08 | IMTX | 3.51 | 0.47 | 0.20 | 9034 |
| 2025-04-09 | IMTX | 4.03 | 0.46 | 0.00 | 9134 |
| 2025-04-10 | IMTX | 3.96 | 0.46 | 0.00 | 9134 |
| 2025-04-11 | IMTX | 4.16 | 0.46 | 0.00 | 9134 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-12 | IMTX | 4.55 | 4.4 | - | -0.69 |
| 2025-03-13 | IMTX | 4.52 | 4.4 | - | -0.69 |
| 2025-03-14 | IMTX | 4.55 | 4.4 | - | -0.69 |
| 2025-03-17 | IMTX | 4.98 | 4.4 | - | -0.69 |
| 2025-03-18 | IMTX | 5.11 | 4.4 | - | -0.69 |
| 2025-03-19 | IMTX | 5.37 | 4.4 | - | -0.69 |
| 2025-03-20 | IMTX | 5.30 | 4.4 | - | -0.69 |
| 2025-03-21 | IMTX | 5.01 | 4.4 | - | -0.69 |
| 2025-03-24 | IMTX | 5.00 | 4.4 | - | -0.69 |
| 2025-03-25 | IMTX | 4.68 | 4.4 | - | -0.69 |
| 2025-03-26 | IMTX | 4.53 | 4.4 | - | -0.69 |
| 2025-03-27 | IMTX | 4.71 | 4.4 | - | -0.69 |
| 2025-03-28 | IMTX | 4.63 | -3.5 | - | -0.69 |
| 2025-03-31 | IMTX | 4.51 | -1098.8 | - | -1.33 |
| 2025-04-01 | IMTX | 4.00 | -1098.8 | - | -1.34 |
| 2025-04-02 | IMTX | 4.17 | -1098.8 | - | -1.34 |
| 2025-04-03 | IMTX | 3.84 | -1098.8 | - | -1.34 |
| 2025-04-04 | IMTX | 3.51 | -1098.8 | - | -1.34 |
| 2025-04-07 | IMTX | 3.68 | -1098.8 | - | -1.34 |
| 2025-04-08 | IMTX | 3.52 | -1098.8 | - | -1.34 |
| 2025-04-09 | IMTX | 4.03 | -1098.8 | - | -1.34 |
| 2025-04-10 | IMTX | 3.95 | -1098.8 | - | -1.34 |
| 2025-04-11 | IMTX | 4.14 | -1098.8 | - | -1.34 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-12 | IMTX | 0.00 | 28.92 | 9.92 |
| 2025-03-13 | IMTX | 0.00 | 28.92 | 9.92 |
| 2025-03-14 | IMTX | 0.00 | 28.92 | 9.92 |
| 2025-03-17 | IMTX | 0.00 | 25.92 | 9.92 |
| 2025-03-18 | IMTX | 0.00 | 25.92 | 9.92 |
| 2025-03-19 | IMTX | 0.00 | 25.92 | 9.92 |
| 2025-03-20 | IMTX | 0.00 | 25.92 | 9.92 |
| 2025-03-21 | IMTX | 0.00 | 25.92 | 9.92 |
| 2025-03-24 | IMTX | 0.00 | 25.87 | 9.92 |
| 2025-03-25 | IMTX | 0.00 | 25.87 | 9.92 |
| 2025-03-26 | IMTX | 0.00 | 25.87 | 9.93 |
| 2025-03-27 | IMTX | 0.00 | 25.87 | 9.93 |
| 2025-03-28 | IMTX | 0.00 | 25.87 | 9.93 |
| 2025-03-31 | IMTX | 0.00 | 25.28 | 9.93 |
| 2025-04-01 | IMTX | 0.00 | 25.28 | 9.93 |
| 2025-04-02 | IMTX | 0.00 | 25.28 | 9.93 |
| 2025-04-03 | IMTX | 0.00 | 25.28 | 9.75 |
| 2025-04-04 | IMTX | 0.00 | 25.28 | 9.75 |
| 2025-04-07 | IMTX | 0.00 | 24.90 | 9.75 |
| 2025-04-08 | IMTX | 0.00 | 24.90 | 9.75 |
| 2025-04-09 | IMTX | 0.00 | 24.90 | 9.75 |
| 2025-04-10 | IMTX | 0.00 | 24.90 | 7.73 |
| 2025-04-11 | IMTX | 0.00 | 24.90 | 7.73 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.48
Avg. EPS Est. Current Quarter
-0.39
Avg. EPS Est. Next Quarter
-0.4
Insider Transactions
Institutional Transactions
24.9
Beta
0.92
Average Sales Estimate Current Quarter
14
Average Sales Estimate Next Quarter
14
Fair Value
Quality Score
67
Growth Score
49
Sentiment Score
34
Actual DrawDown %
77.6
Max Drawdown 5-Year %
Target Price
16.86
P/E
51.36
Forward P/E
PEG
P/S
2.98
P/B
0.85
P/Free Cash Flow
EPS
0.08
Average EPS Est. Cur. Y
-1.34
EPS Next Y. (Est.)
-1.54
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
9.33
Relative Volume
0.45
Return on Equity vs Sector %
-16.9
Return on Equity vs Industry %
-4.1
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.09
EBIT Estimation
Immatics N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 554
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
stock quote shares IMTX – Immatics N.V Stock Price stock today
news today IMTX – Immatics N.V stock forecast ,stock prediction 2023 2024 2025
marketwatch IMTX – Immatics N.V yahoo finance google finance
stock history IMTX – Immatics N.V invest stock market
stock prices IMTX premarket after hours
ticker IMTX fair value insiders trading